메뉴 건너뛰기




Volumn 11, Issue 1, 2013, Pages

Novel therapeutic agents in clinical development for systemic lupus erythematosus

Author keywords

B cell depletion; BLys; Interferon , SLE; Lupus nephritis; T cell co stimulation

Indexed keywords

ABATACEPT; ALPHA INTERFERON; ATACICEPT; BELIMUMAB; BLISIBIMOD; CD40 LIGAND; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPRATUZUMAB; FOSTAMATINIB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; LAQUINIMOD; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PLACEBO; RITUXIMAB; RONTALIZUMAB; SIFALIMUMAB; TABALUMAB; TOCILIZUMAB; TOFACITINIB;

EID: 84876959366     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-120     Document Type: Review
Times cited : (18)

References (60)
  • 1
    • 84858429634 scopus 로고    scopus 로고
    • Systemic lupus erythematosus one disease or many?
    • 10.1016/j.autrev.2011.10.020, 22041578
    • Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y. Systemic lupus erythematosus one disease or many?. Autoimmun Rev 2012, 11:593-595. 10.1016/j.autrev.2011.10.020, 22041578.
    • (2012) Autoimmun Rev , vol.11 , pp. 593-595
    • Agmon-Levin, N.1    Mosca, M.2    Petri, M.3    Shoenfeld, Y.4
  • 2
    • 40049093765 scopus 로고    scopus 로고
    • Systemic lupus erythematosus
    • 10.1056/NEJMra071297, 18305268
    • Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939. 10.1056/NEJMra071297, 18305268.
    • (2008) N Engl J Med , vol.358 , pp. 929-939
    • Rahman, A.1    Isenberg, D.A.2
  • 3
    • 0030065933 scopus 로고    scopus 로고
    • Undiagnosed systemic lupus erythematosus in the community
    • 10.1016/S0140-6736(96)90539-5, 8598703
    • Johnson AE, Gordon C, Hobbs FD, Bacon PA. Undiagnosed systemic lupus erythematosus in the community. Lancet 1996, 347:367-369. 10.1016/S0140-6736(96)90539-5, 8598703.
    • (1996) Lancet , vol.347 , pp. 367-369
    • Johnson, A.E.1    Gordon, C.2    Hobbs, F.D.3    Bacon, P.A.4
  • 5
    • 0042887356 scopus 로고    scopus 로고
    • Lupus nephritis: current issues
    • 10.1136/ard.62.9.795, 1754664, 12922947
    • Mavragani CP, Moutsopoulos HM. Lupus nephritis: current issues. Ann Rheum Dis 2003, 62:795-798. 10.1136/ard.62.9.795, 1754664, 12922947.
    • (2003) Ann Rheum Dis , vol.62 , pp. 795-798
    • Mavragani, C.P.1    Moutsopoulos, H.M.2
  • 6
    • 33846063760 scopus 로고    scopus 로고
    • Severe lupus nephritis: racial differences in presentation and outcome
    • 10.1681/ASN.2006090992, 17167111
    • Korbet SM, Schwartz MM, Evans J, Lewis EJ. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007, 18:244-254. 10.1681/ASN.2006090992, 17167111.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 244-254
    • Korbet, S.M.1    Schwartz, M.M.2    Evans, J.3    Lewis, E.J.4
  • 7
    • 80155204725 scopus 로고    scopus 로고
    • Assessment of a lupus nephritis cohort over a 30-year period
    • Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 2011, 50:1424-1430.
    • (2011) Rheumatology (Oxford) , vol.50 , pp. 1424-1430
    • Croca, S.C.1    Rodrigues, T.2    Isenberg, D.A.3
  • 9
    • 0033883546 scopus 로고    scopus 로고
    • Damage in systemic lupus erythematosus and its association with corticosteroids
    • 10.1002/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O, 10943870
    • Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000, 43:1801-1808. 10.1002/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O, 10943870.
    • (2000) Arthritis Rheum , vol.43 , pp. 1801-1808
    • Zonana-Nacach, A.1    Barr, S.G.2    Magder, L.S.3    Petri, M.4
  • 10
    • 77953182426 scopus 로고    scopus 로고
    • B cells as therapeutic targets in SLE
    • 10.1038/nrrheum.2010.68, 20520647
    • Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6:326-337. 10.1038/nrrheum.2010.68, 20520647.
    • (2010) Nat Rev Rheumatol , vol.6 , pp. 326-337
    • Sanz, I.1    Lee, F.E.2
  • 12
    • 74849131972 scopus 로고    scopus 로고
    • Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
    • 10.1002/art.27233, 20039413
    • Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233. 10.1002/art.27233, 20039413.
    • (2010) Arthritis Rheum , vol.62 , pp. 222-233
    • Merrill, J.T.1    Neuwelt, C.M.2    Wallace, D.J.3    Shanahan, J.C.4    Latinis, K.M.5    Oates, J.C.6    Utset, T.O.7    Gordon, C.8    Isenberg, D.A.9    Hsieh, H.J.10    Zhang, D.11    Brunetta, P.G.12
  • 13
    • 84866184129 scopus 로고    scopus 로고
    • Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study
    • 10.1002/art.34359, 22231479, LUNAR Investigator Group
    • Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G, LUNAR Investigator Group Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012, 64:1215-1226. 10.1002/art.34359, 22231479, LUNAR Investigator Group.
    • (2012) Arthritis Rheum , vol.64 , pp. 1215-1226
    • Rovin, B.H.1    Furie, R.2    Latinis, K.3    Looney, R.J.4    Fervenza, F.C.5    Sanchez-Guerrero, J.6    Maciuca, R.7    Zhang, D.8    Garg, J.P.9    Brunetta, P.10    Appel, G.11
  • 15
    • 56749181048 scopus 로고    scopus 로고
    • Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies
    • 10.1136/ard.2008.097972, 19022817
    • Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 2008, 67:iii64-iii65. 10.1136/ard.2008.097972, 19022817.
    • (2008) Ann Rheum Dis , vol.67 , pp. 364-365
    • Calabrese, L.H.1    Molloy, E.S.2
  • 16
    • 71049118062 scopus 로고    scopus 로고
    • Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
    • 10.1093/ndt/gfp336, 19617257
    • Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, Lightstone L, Cairns T. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009, 24:3717-3723. 10.1093/ndt/gfp336, 19617257.
    • (2009) Nephrol Dial Transplant , vol.24 , pp. 3717-3723
    • Pepper, R.1    Griffith, M.2    Kirwan, C.3    Levy, J.4    Taube, D.5    Pusey, C.6    Lightstone, L.7    Cairns, T.8
  • 17
    • 84858393494 scopus 로고    scopus 로고
    • The landscape after LUNAR: rituximab's crater-filled path
    • 10.1002/art.34362, 22231618
    • Lightstone L. The landscape after LUNAR: rituximab's crater-filled path. Arthritis Rheum 2012, 64:962-965. 10.1002/art.34362, 22231618.
    • (2012) Arthritis Rheum , vol.64 , pp. 962-965
    • Lightstone, L.1
  • 18
    • 78650997402 scopus 로고    scopus 로고
    • Treatment of systemic lupus erythematosus with epratuzumab
    • 10.1111/j.1365-2125.2010.03767.x, 3040537, 21219397
    • Traczewski P, Rudnicka L. Treatment of systemic lupus erythematosus with epratuzumab. Br J Clin Pharmacol 2011, 71:175-182. 10.1111/j.1365-2125.2010.03767.x, 3040537, 21219397.
    • (2011) Br J Clin Pharmacol , vol.71 , pp. 175-182
    • Traczewski, P.1    Rudnicka, L.2
  • 19
    • 41849121941 scopus 로고    scopus 로고
    • Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls
    • Jacobi AM, Goldenberg DM, Hiepe F, Radbruch A, Burmester GR, Dorner T. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008, 67:450-457.
    • (2008) Ann Rheum Dis , vol.67 , pp. 450-457
    • Jacobi, A.M.1    Goldenberg, D.M.2    Hiepe, F.3    Radbruch, A.4    Burmester, G.R.5    Dorner, T.6
  • 20
    • 84865479037 scopus 로고    scopus 로고
    • B-cell depletion in the treatment of lupus nephritis
    • 10.1038/nrneph.2012.141, 22801948
    • Gregersen JW, Jayne DR. B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol 2012, 8:505-514. 10.1038/nrneph.2012.141, 22801948.
    • (2012) Nat Rev Nephrol , vol.8 , pp. 505-514
    • Gregersen, J.W.1    Jayne, D.R.2
  • 21
    • 80052416880 scopus 로고    scopus 로고
    • Are autoantibodies the targets of B-cell-directed therapy?
    • 10.1038/nrrheum.2011.108, 21808289
    • Pisetsky DS, Grammer AC, Ning TC, Lipsky PE. Are autoantibodies the targets of B-cell-directed therapy?. Nat Rev Rheumatol 2011, 7:551-556. 10.1038/nrrheum.2011.108, 21808289.
    • (2011) Nat Rev Rheumatol , vol.7 , pp. 551-556
    • Pisetsky, D.S.1    Grammer, A.C.2    Ning, T.C.3    Lipsky, P.E.4
  • 24
    • 84863850571 scopus 로고    scopus 로고
    • Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
    • 10.1136/annrheumdis-2011-200937, 3396451, 22337213
    • van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012, 71:1343-1349. 10.1136/annrheumdis-2011-200937, 3396451, 22337213.
    • (2012) Ann Rheum Dis , vol.71 , pp. 1343-1349
    • van Vollenhoven, R.F.1    Petri, M.A.2    Cervera, R.3    Roth, D.A.4    Ji, B.N.5    Kleoudis, C.S.6    Zhong, Z.J.7    Freimuth, W.8
  • 25
    • 67651004925 scopus 로고    scopus 로고
    • Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections
    • 10.1128/CMR.00001-09, 2708392, 19597006
    • Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev 2009, 22:396-414. 10.1128/CMR.00001-09, 2708392, 19597006.
    • (2009) Clin Microbiol Rev , vol.22 , pp. 396-414
    • Fried, A.J.1    Bonilla, F.A.2
  • 26
    • 84155163019 scopus 로고    scopus 로고
    • Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus
    • 10.1038/clpt.2011.290, 22130121
    • Dennis GJ. Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus. Clin Pharmacol Ther 2012, 91:143-149. 10.1038/clpt.2011.290, 22130121.
    • (2012) Clin Pharmacol Ther , vol.91 , pp. 143-149
    • Dennis, G.J.1
  • 27
    • 84859338406 scopus 로고    scopus 로고
    • Biologicals for the treatment of systemic lupus erythematosus?
    • 10.3109/07853890.2011.561362, 21495789
    • Gunnarsson I, van Vollenhoven RF. Biologicals for the treatment of systemic lupus erythematosus?. Ann Med 2012, 44:225-232. 10.3109/07853890.2011.561362, 21495789.
    • (2012) Ann Med , vol.44 , pp. 225-232
    • Gunnarsson, I.1    van Vollenhoven, R.F.2
  • 28
    • 84856795563 scopus 로고    scopus 로고
    • Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial
    • 10.1186/ar3738, 3392829, 22325903
    • Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer NG. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012, 14:R33. 10.1186/ar3738, 3392829, 22325903.
    • (2012) Arthritis Res Ther , vol.14
    • Ginzler, E.M.1    Wax, S.2    Rajeswaran, A.3    Copt, S.4    Hillson, J.5    Ramos, E.6    Singer, N.G.7
  • 29
    • 79959832697 scopus 로고    scopus 로고
    • Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial
    • 10.1002/art.30373, 21452293
    • Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, Tak PP. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 2011, 63:1793-1803. 10.1002/art.30373, 21452293.
    • (2011) Arthritis Rheum , vol.63 , pp. 1793-1803
    • Genovese, M.C.1    Kinnman, N.2    de La Bourdonnaye, G.3    Pena Rossi, C.4    Tak, P.P.5
  • 30
    • 0031730773 scopus 로고    scopus 로고
    • Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor
    • 10.1007/BF02788753, 9844829
    • Scheipers P, Reiser H. Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor. Immunol Res 1998, 18:103-115. 10.1007/BF02788753, 9844829.
    • (1998) Immunol Res , vol.18 , pp. 103-115
    • Scheipers, P.1    Reiser, H.2
  • 31
    • 0029851224 scopus 로고    scopus 로고
    • Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases
    • 10.1056/NEJM199610313351807, 8857022
    • Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996, 335:1369-1377. 10.1056/NEJM199610313351807, 8857022.
    • (1996) N Engl J Med , vol.335 , pp. 1369-1377
    • Reiser, H.1    Stadecker, M.J.2
  • 33
    • 0035284737 scopus 로고    scopus 로고
    • Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide
    • Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001, 166:2913-2916.
    • (2001) J Immunol , vol.166 , pp. 2913-2916
    • Daikh, D.I.1    Wofsy, D.2
  • 34
    • 2342495275 scopus 로고    scopus 로고
    • Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide
    • 10.1002/art.20147, 15146424
    • Cunnane G, Chan OT, Cassafer G, Brindis S, Kaufman E, Yen TS, Daikh DI. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum 2004, 50:1539-1548. 10.1002/art.20147, 15146424.
    • (2004) Arthritis Rheum , vol.50 , pp. 1539-1548
    • Cunnane, G.1    Chan, O.T.2    Cassafer, G.3    Brindis, S.4    Kaufman, E.5    Yen, T.S.6    Daikh, D.I.7
  • 35
    • 0028483990 scopus 로고
    • Treatment of murine lupus with CTLA4Ig
    • 10.1126/science.7520604, 7520604
    • Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994, 265:1225-1227. 10.1126/science.7520604, 7520604.
    • (1994) Science , vol.265 , pp. 1225-1227
    • Finck, B.K.1    Linsley, P.S.2    Wofsy, D.3
  • 36
    • 77957682858 scopus 로고    scopus 로고
    • The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial
    • 10.1002/art.27601, 20533545
    • Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:3077-3087. 10.1002/art.27601, 20533545.
    • (2010) Arthritis Rheum , vol.62 , pp. 3077-3087
    • Merrill, J.T.1    Burgos-Vargas, R.2    Westhovens, R.3    Chalmers, A.4    D'Cruz, D.5    Wallace, D.J.6    Bae, S.C.7    Sigal, L.8    Becker, J.C.9    Kelly, S.10    Raghupathi, K.11    Li, T.12    Peng, Y.13    Kinaszczuk, M.14    Nash, P.15
  • 37
    • 84863756711 scopus 로고    scopus 로고
    • Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, random- ized, double-blind, placebo-controlled phase II/III study [abstract]
    • Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, random- ized, double-blind, placebo-controlled phase II/III study [abstract]. Arthritis Rheum 2011, 63(Suppl):S962-3.
    • (2011) Arthritis Rheum , vol.63 , Issue.SUPPL
    • Furie, R.1    Nicholls, K.2    Cheng, T.T.3    Houssiau, F.4    Burgos-Vargas, R.5    Chen, S.L.6
  • 38
    • 84878421687 scopus 로고    scopus 로고
    • Comparison of alternative primary outcome measures for use in a lupus nephritis trial
    • [Epub ahead of print]
    • Wofsy D, Hillson JL, Diamond B. Comparison of alternative primary outcome measures for use in a lupus nephritis trial. Arthritis Rheum 2013, [Epub ahead of print].
    • (2013) Arthritis Rheum
    • Wofsy, D.1    Hillson, J.L.2    Diamond, B.3
  • 39
    • 0038240916 scopus 로고    scopus 로고
    • Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE)
    • 10.1111/j.1749-6632.2003.tb06048.x, 12727639
    • Davidson A, Wang X, Mihara M, Ramanujam M, Huang W, Schiffer L, Sinha J. Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE). Ann N Y Acad Sci 2003, 987:188-198. 10.1111/j.1749-6632.2003.tb06048.x, 12727639.
    • (2003) Ann N Y Acad Sci , vol.987 , pp. 188-198
    • Davidson, A.1    Wang, X.2    Mihara, M.3    Ramanujam, M.4    Huang, W.5    Schiffer, L.6    Sinha, J.7
  • 40
    • 0030267659 scopus 로고    scopus 로고
    • Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response
    • Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996, 157:3159-3164.
    • (1996) J Immunol , vol.157 , pp. 3159-3164
    • Early, G.S.1    Zhao, W.2    Burns, C.M.3
  • 41
    • 0036899589 scopus 로고    scopus 로고
    • Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial
    • 10.1002/art.10681, 12483729
    • Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:3251-3258. 10.1002/art.10681, 12483729.
    • (2002) Arthritis Rheum , vol.46 , pp. 3251-3258
    • Kalunian, K.C.1    Davis, J.C.2    Merrill, J.T.3    Totoritis, M.C.4    Wofsy, D.5
  • 42
    • 0037333857 scopus 로고    scopus 로고
    • A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
    • 10.1002/art.10856, 12632425
    • Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003, 48:719-727. 10.1002/art.10856, 12632425.
    • (2003) Arthritis Rheum , vol.48 , pp. 719-727
    • Boumpas, D.T.1    Furie, R.2    Manzi, S.3    Illei, G.G.4    Wallace, D.J.5    Balow, J.E.6    Vaishnaw, A.7
  • 43
    • 0028355713 scopus 로고
    • Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice
    • 1887352, 8178944
    • Ryffel B, Car BD, Gunn H, Roman D, Hiestand P, Mihatsch MJ. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol 1994, 144:927-937. 1887352, 8178944.
    • (1994) Am J Pathol , vol.144 , pp. 927-937
    • Ryffel, B.1    Car, B.D.2    Gunn, H.3    Roman, D.4    Hiestand, P.5    Mihatsch, M.J.6
  • 44
    • 2442593227 scopus 로고    scopus 로고
    • Experimental study on intramuscular injection of eukaryotic expression vector pcDNA3- IL-6 on BXSB mice
    • Yang G, Liu H, Jiang M, Jiang X, Li S, Yuan Y, Ma D. Experimental study on intramuscular injection of eukaryotic expression vector pcDNA3- IL-6 on BXSB mice. Chin Med J (Engl) 1998, 111:38-42.
    • (1998) Chin Med J (Engl) , vol.111 , pp. 38-42
    • Yang, G.1    Liu, H.2    Jiang, M.3    Jiang, X.4    Li, S.5    Yuan, Y.6    Ma, D.7
  • 45
    • 33750011260 scopus 로고    scopus 로고
    • Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus
    • 10.1111/j.1365-2567.2006.02433.x, 1819578, 17067309
    • Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006, 119:296-305. 10.1111/j.1365-2567.2006.02433.x, 1819578, 17067309.
    • (2006) Immunology , vol.119 , pp. 296-305
    • Liang, B.1    Gardner, D.B.2    Griswold, D.E.3    Bugelski, P.J.4    Song, X.Y.5
  • 46
    • 0031861643 scopus 로고    scopus 로고
    • IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice
    • 10.1046/j.1365-2249.1998.00612.x, 1904997, 9649207
    • Mihara M, Takagi N, Takeda Y, Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 1998, 112:397-402. 10.1046/j.1365-2249.1998.00612.x, 1904997, 9649207.
    • (1998) Clin Exp Immunol , vol.112 , pp. 397-402
    • Mihara, M.1    Takagi, N.2    Takeda, Y.3    Ohsugi, Y.4
  • 49
    • 0030457978 scopus 로고    scopus 로고
    • Serum and urinary interleukin-6 in systemic lupus erythematosus
    • 10.1177/096120339600500603, 9116699
    • Peterson E, Robertson AD, Emlen W. Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus 1996, 5:571-575. 10.1177/096120339600500603, 9116699.
    • (1996) Lupus , vol.5 , pp. 571-575
    • Peterson, E.1    Robertson, A.D.2    Emlen, W.3
  • 50
    • 0033623775 scopus 로고    scopus 로고
    • Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis
    • 10.1159/000045663, 10867535
    • Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY. Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 2000, 85:207-214. 10.1159/000045663, 10867535.
    • (2000) Nephron , vol.85 , pp. 207-214
    • Tsai, C.Y.1    Wu, T.H.2    Yu, C.L.3    Lu, J.Y.4    Tsai, Y.Y.5
  • 51
    • 75749113331 scopus 로고    scopus 로고
    • Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study
    • 10.1002/art.27221, 3057537, 20112381
    • Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010, 62:542-552. 10.1002/art.27221, 3057537, 20112381.
    • (2010) Arthritis Rheum , vol.62 , pp. 542-552
    • Illei, G.G.1    Shirota, Y.2    Yarboro, C.H.3    Daruwalla, J.4    Tackey, E.5    Takada, K.6    Fleisher, T.7    Balow, J.E.8    Lipsky, P.E.9
  • 53
    • 0242456113 scopus 로고    scopus 로고
    • Microarray analysis of gene expression in lupus
    • 10.1186/ar1015, 333417, 14680503
    • Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003, 5:279-287. 10.1186/ar1015, 333417, 14680503.
    • (2003) Arthritis Res Ther , vol.5 , pp. 279-287
    • Crow, M.K.1    Wohlgemuth, J.2
  • 54
    • 18644384042 scopus 로고    scopus 로고
    • Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease
    • 10.1002/art.21031, 15880830
    • Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005, 52:1491-1503. 10.1002/art.21031, 15880830.
    • (2005) Arthritis Rheum , vol.52 , pp. 1491-1503
    • Kirou, K.A.1    Lee, C.2    George, S.3    Louca, K.4    Peterson, M.G.5    Crow, M.K.6
  • 55
    • 80053562466 scopus 로고    scopus 로고
    • Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study
    • 10.1136/ard.2010.144485, 21798883, Lupus Interferon Skin Activity (LISA) Study Investigators
    • Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B, Lupus Interferon Skin Activity (LISA) Study Investigators Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011, 70:1905-1913. 10.1136/ard.2010.144485, 21798883, Lupus Interferon Skin Activity (LISA) Study Investigators.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1905-1913
    • Merrill, J.T.1    Wallace, D.J.2    Petri, M.3    Kirou, K.A.4    Yao, Y.5    White, W.I.6    Robbie, G.7    Levin, R.8    Berney, S.M.9    Chindalore, V.10    Olsen, N.11    Richman, L.12    Le, C.13    Jallal, B.14    White, B.15
  • 56
    • 53749090207 scopus 로고    scopus 로고
    • Novel therapies in lupus - focus on nephritis
    • Cordeiro AC, Isenberg DA. Novel therapies in lupus - focus on nephritis. Acta Reumatol Port 2008, 33:157-169.
    • (2008) Acta Reumatol Port , vol.33 , pp. 157-169
    • Cordeiro, A.C.1    Isenberg, D.A.2
  • 57
    • 0029764359 scopus 로고    scopus 로고
    • Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5
    • 10.1073/pnas.93.16.8563, 38712, 8710910
    • Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A 1996, 93:8563-8568. 10.1073/pnas.93.16.8563, 38712, 8710910.
    • (1996) Proc Natl Acad Sci U S A , vol.93 , pp. 8563-8568
    • Wang, Y.1    Hu, Q.2    Madri, J.A.3    Rollins, S.A.4    Chodera, A.5    Matis, L.A.6
  • 58
    • 2942716917 scopus 로고    scopus 로고
    • Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus
    • 10.1191/0961203303lu1021oa, 15230287
    • Rother RP, Mojcik CF, McCroskery EW. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus 2004, 13:328-334. 10.1191/0961203303lu1021oa, 15230287.
    • (2004) Lupus , vol.13 , pp. 328-334
    • Rother, R.P.1    Mojcik, C.F.2    McCroskery, E.W.3
  • 60
    • 84867804298 scopus 로고    scopus 로고
    • The status of fostamatinib in the treatment of rheumatoid arthritis
    • 10.1586/eci.12.63, 23078058
    • Morales-Torres J. The status of fostamatinib in the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2012, 8:609-615. 10.1586/eci.12.63, 23078058.
    • (2012) Expert Rev Clin Immunol , vol.8 , pp. 609-615
    • Morales-Torres, J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.